ORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...

A novel therapy for atopic dermatitis (AD) led to at least 75% improvement in a third of patients after 6 months, a ...

Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...

Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease ...

Upadacitinib is potentially safe and effective for patients with moderate to severe atopic dermatitis, irrespective of ...

In terms of how underarm dermatitis presents, you may notice several different symptoms, including “redness, itching, ...

Eli Lilly (NYSE:LLY) saw a notable 10% increase in its stock price over the last month, driven by several important events.

Lebrikizumab is comparable or superior to many advanced systemic monotherapies for the short-term treatment of atopic dermatitis.

Topical roflumilast, 0.05%, is under consideration for treating mild to moderate atopic dermatitis in children aged 2-5 years.

Lawrence F. Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the effectiveness of ruxolitinib cream as a nonsteroidal topical treatment for atopic ...

Once-daily roflumilast cream 0.05% is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 years, according ...

The global canine atopic dermatitis market is experiencing significant growth, projected to escalate from US$ 231.4 Mn in ...